News from savara pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 06, 2014, 07:30 ET

Savara Pharmaceuticals Raises $10 Million to Advance AeroVanc for MRSA Lung Infection in People with Cystic Fibrosis

 Savara Pharmaceuticals announced today that it closed a $10 million bridge financing round to support the  development of AeroVanc, the...

Dec 10, 2013, 08:00 ET

Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc

Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic product,...

Dec 05, 2013, 08:00 ET

Savara Pharmaceuticals Appoints Two New Members to Its Board of Directors

Savara Pharmaceuticals announced today that the company has appointed Dr. Joseph S. McCracken, DVM and Yuri Pikover to its Board of Directors....

Oct 17, 2013, 08:00 ET

Cystic Fibrosis Foundation Therapeutics Provides Savara Pharmaceuticals $1.7 Million Award for Development of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients

Savara Pharmaceuticals announced today it has received a $1.7 million research award from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the...

Apr 18, 2013, 08:00 ET

Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients

Savara Pharmaceuticals announced today that the first patient has started study drug treatment in a Phase 2 clinical trial evaluating the safety and...

Feb 26, 2013, 08:00 ET

Savara Pharmaceuticals Announces Formation of Clinical Advisory Board

 Savara Pharmaceuticals today announced the formation of its Clinical Advisory Board to provide clinical guidance to the company as it advances...

Nov 13, 2012, 08:00 ET

Savara Pharmaceuticals' AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients

 Savara Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to AeroVanc™...

Jun 12, 2012, 08:30 ET

Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients

 Savara Pharmaceuticals, an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and...

Jun 12, 2012, 08:30 ET

Savara Pharmaceuticals Raises $8.6 Million in Series B Financing Round

 Savara Pharmaceuticals, an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and...

Jun 09, 2009, 13:34 ET

Savara Closes Series A Financing Round

- Funds Raised Will Be Used to Expand Technology into New Pulmonary Markets - Savara Pharmaceuticals, a biotechnology inhalation drug delivery...